{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:45:25Z","timestamp":1791405925907,"version":"4.3.3"},"reference-count":16,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T00:00:00Z","timestamp":1282089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a disease\u2010modifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg\/d) and 27 to placebo. The change in Total Functional Capacity (TFC) score from baseline to Mo 18 was prespecified as the primary measure of HD progression. By using a futility design, we tested the null hypothesis that minocycline would reduce the mean decline in TFC score by at least 25% compared to a fixed value obtained from a historical database, with a one\u2010tailed significance level of 10%. The placebo group was included to facilitate blinding. Rejection of the null hypothesis would discourage a major definitive trial of minocycline in HD. For the primary analysis, missing data were handled by carrying forward the last available observation; a secondary analysis used multiple imputations. The mean TFC decline in the minocycline group was 1.55 (SD 1.85), and futility was not declared (<jats:italic>P<\/jats:italic> = 0.12) for the primary analysis. When multiple imputation was used to handle missing data, the mean TFC decline in the minocycline group of 1.71 (SD 1.96, <jats:italic>P<\/jats:italic> = 0.07) suggested futility, as was the case for prespecified secondary outcome measures. There were no safety abnormalities attributable to minocycline. Based on the threshold of 25% improvement in TFC, further study of minocycline 200 mg\/d in HD was not warranted. Futility designs aid in screening potential therapies for HD. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23236","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T22:59:21Z","timestamp":1282172361000},"page":"2219-2224","source":"Crossref","is-referenced-by-count":90,"title":["A futility study of minocycline in Huntington's disease"],"prefix":"10.1002","volume":"25","author":[{"given":"Merit","family":"Cudkowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Huntington Study Group DOMINO Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"491","volume-title":"Movement disorders: neurologic principles and practice","author":"Marshall F","year":"1997"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1832501100"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/417074a"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/77528"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2005.11.002"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10614"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022366"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250308"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo\u2010controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","author":"Huntington Study Group (Kieburtz K, principal author)","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2307\/2532847"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000133403.30559.FF"},{"issue":"1","key":"e_1_2_6_15_2","first-page":"A90","article-title":"Results of the phase III randomized controlled trial of minocycline in ALS","volume":"68","author":"Gordon PH","year":"2007","journal-title":"Neurology"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000277487.04281.db"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23236","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:53:50Z","timestamp":1760957630000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":16,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,10,15]]}},"alternative-id":["10.1002\/mds.23236"],"URL":"https:\/\/doi.org\/10.1002\/mds.23236","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,18]]}}}